Volume 14, Issue 2 ( June 2022 2022)                   Iranian Journal of Blood and Cancer 2022, 14(2): 85-91 | Back to browse issues page


XML Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Prasetya A, Soetedjo R, Saputra Arifin E. CAR-NK Cells: A Systematic Review of Emerging Alternative on Immunotherapy Against Leukemia. Iranian Journal of Blood and Cancer 2022; 14 (2) :85-91
URL: http://ijbc.ir/article-1-1102-en.html
1- School of Medicine and Health Sciences Atma Jaya Catholic University of Indonesia , prasetyaalver@gmail.com
2- School of Medicine and Health Sciences Atma Jaya Catholic University of Indonesia
Abstract:   (1055 Views)

Background: Cancer is a public health emergency. It has a high mortality rate despite numerous studies on pharmaceutical therapies. Chimeric antigen receptor-natural killer (CAR-NK) cells are promising immunotherapy that could be used to treat cancer, especially leukemia. However, the evidence is still unclear. Thus, this systematic review aims to summarize the evidence regarding the use of CAR-NK cells as a therapy for leukemia.
Method: This systematic review was conducted in accordance with the preferred reporting items for systematic reviews and meta-analysis (PRISMA) statement guidelines. The literature search was done using PubMed, ProQuest, ScienceDirect, and EBSCOHost with “chimeric antigen receptor”, “natural killer cell”, and “leukemia” as the primary keywords until 20 March 2020. Data collection and extraction were done by three independent reviewers. Extending a risk-of-bias approach to address in-vitro studies for assessing the risk of bias was utilized in the quality assessment of the studies.
Results: The search strategy identified 221 studies. Three relevant articles met our inclusion criteria. All the included studies had a low risk of bias. The main findings from available data were as follows: (a) cytotoxicities of CAR-NK cells were found highest in cell lines expressing antigen for CAR (CD19+ cancer cells) (b) CAR-NK cells had low cytotoxicities against cells that didn’t express antigen for CAR (e.g. SR-91); (c) all studies did not result in aberrant growth of the transduced CAR-NK cells.
Conclusion: The use of CAR-NK cells showed promising results in treating leukemia based on its cytotoxicity against CD19+ cancer cell lines.

Full-Text [PDF 646 kb]   (525 Downloads)    
: Review Article | Subject: Pediatric Hematology & Oncology
Received: 2021/12/30 | Accepted: 2022/06/7 | Published: 2022/06/28

References
1. Kampen KR. The discovery and early understanding of leukemia. Leukemia Research. 2012 Jan;36(1):6-13. [DOI:10.1016/j.leukres.2011.09.028]
2. Global Cancer Observatory [Internet]. Gco.iarc.fr. 2020 [cited 16 July 2020]. Available from: https://gco.iarc.fr
3. Side Effects | Leukemia and Lymphoma Society [Internet]. Lls.org. 2020 [cited 16 July 2020]. Available from: https://www.lls.org/leukemia/acute-lymphoblastic-leukemia/treatment/side-effects
4. Immunotherapy for Cancer [Internet]. National Cancer Institute. 2020 [cited 16 July 2020]. Available from: https://www.cancer.gov/about-cancer/treatment/types/immunotherapy
5. Lim W, June C. The Principles of Engineering Immune Cells to Treat Cancer. Cell. 2017;168(4):724-740. [DOI:10.1016/j.cell.2017.01.016]
6. CAR T-Cell Therapy Approved for Children, Young Adults with Leukemia [Internet]. National Cancer Institute. 2017 [cited 16 July 2020]. Available from: https://www.cancer.gov/news-events/cancer-currents-blog/2017/tisagenlecleucel-fda-childhood-leukemia.
7. Habib S, Tariq SM, Tariq M. Chimeric Antigen Receptor-Natural Killer Cells: The Future of Cancer Immunotherapy. Ochsner J. 2019; 19: 186-187. [DOI:10.31486/toj.19.0033]
8. Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev. 2015 Jan 1;4:1. [DOI:10.1186/2046-4053-4-1]
9. Rooney A. Extending a Risk-of-Bias Approach to Address in Vitro Studies. National Toxicology Program Office of Health Assessment and Translation. 2015.
10. E Liu, Y Tong, G Dotti, H Shaim, B Savoldo, M Mukherjee, et al. Cord blood NK cells engineered to express IL-15 and a CD19-targeted CAR show long-term persistence and potent antitumor activity. Leukemia 2018; 32: 520-531. [DOI:10.1038/leu.2017.226]
11. Boissel L, Betancur M, Wels WS, Tuncer H, Klingemann H. Transfection with mRNA for CD19 specific chimeric antigen receptor restores NK cell mediated killing of CLL cells. Leukemia Research 2009; 33: 1255-1259. [DOI:10.1016/j.leukres.2008.11.024]
12. Shimasaki N, Fujisaki H, Cho D, Masselli M, Lockey T, Eldridge P, et al. A clinically adaptable method to enhance the cytotoxicity of natural killer cells against B-cell malignancies. Cytotherapy 2012; 14: 830-840. [DOI:10.3109/14653249.2012.671519]
13. Fitzgerald J, Weiss S, Maude S, Barrett D, Lacey S, Melenhorst J et al. Cytokine Release Syndrome After Chimeric Antigen Receptor T Cell Therapy for Acute Lymphoblastic Leukemia. Critical Care Medicine. 2017;45(2):e124-e131. [DOI:10.1097/CCM.0000000000002053]
14. Rubnitz J, Inaba H, Ribeiro R, Pounds S, Rooney B, Bell T et al. NKAML: A Pilot Study to Determine the Safety and Feasibility of Haploidentical Natural Killer Cell Transplantation in Childhood Acute Myeloid Leukemia. Journal of Clinical Oncology. 2010;28(6):955-959. [DOI:10.1200/JCO.2009.24.4590]
15. Boissel L, Betancur M, Lu W, Wels WS, Marino T, Van RA et al. Comparison of mRNA and lentiviral based transfection of natural killer cells with chimeric antigen receptors recognizing lymphoid antigens. Leukemia & Lymphoma. 2012; 53: 958-965. [DOI:10.3109/10428194.2011.634048]
16. Matosevic S. Viral and Nonviral Engineering of Natural Killer Cells as Emerging Adoptive Cancer Immunotherapies. Journal of Immunology Research. 2018;2018:1-20. [DOI:10.1155/2018/4054815]
17. Li L, Liu LN, Feller S, Allen C, Shivakumar R, Fratantoni J et al. Expression of chimeric antigen receptors in natural killer cells with a regulatory-compliant non-viral method. Cancer Gene Therapy. 2009;17(3):147-154. [DOI:10.1038/cgt.2009.61]
18. Liu E, Marin D, Banerjee P, Macapinlac HA, Thompson P, Basar R et al. Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors. N Engl J Med. 2020; 382: 545-553. [DOI:10.1056/NEJMoa1910607]

Add your comments about this article : Your username or Email:
CAPTCHA

Send email to the article author


Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2024 All Rights Reserved | Iranian Journal of Blood and Cancer

Designed & Developed by : Yektaweb